

Research Article

Association of RNA m⁷G Modification Gene Polymorphisms with Pediatric Glioma Risk

Jinhong Zhu ^{1,2}, Xiaoping Liu,³ Wei Chen,¹ Yuxiang Liao,⁴ Jiabin Liu,¹ Li Yuan,⁵ Jichen Ruan,⁶ and Jing He ¹

¹Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangdong Provincial Key Laboratory of Research in Structural Birth Defect Disease, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangdong Provincial Clinical Research Center for Child Health, Guangzhou, 510623 Guangdong, China

²Department of Clinical Laboratory, Biobank, Harbin Medical University Cancer Hospital, Harbin, 150040 Heilongjiang, China

³Department of Hematology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623 Guangdong, China

⁴Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, 410008 Hunan, China

⁵Department of Pathology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, 510623 Guangdong, China

⁶Department of Hematology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, 325027 Zhejiang, China

Correspondence should be addressed to Jing He; hejing198374@gmail.com

Received 26 September 2022; Revised 14 January 2023; Accepted 20 January 2023; Published 24 January 2023

Academic Editor: Yue Sheng

Copyright © 2023 Jinhong Zhu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Glioma stemming from glial cells of the central nervous system (CNS) is one of the leading causes of cancer death in childhood. The genetic predisposition of glioma is not fully understood. METTL1-WDR4 methyltransferase complex is implicated in tumorigenesis by catalyzing N⁷-methylguanosine (m⁷G) modification of RNA. This study is aimed at determining the association of glioma risk with three polymorphisms (rs2291617, rs10877013, and rs10877012) in *METTL1* and five polymorphisms (rs2156315, rs2156316, rs6586250, rs15736, and rs2248490) in *WDR4* gene in children of Chinese Han. We enrolled 314 cases and 380 controls from three independent hospitals. Genotypes of these polymorphisms were determined using the TaqMan assay. We found the *WDR4* gene rs15736 was significantly associated with reduced glioma risk (GA/AA vs. GG: adjusted odds ratio = 0.63, 95% confidence interval = 0.42 – 0.94, $P = 0.023$) out of the eight studied polymorphisms. Stratified analyses showed that the association of rs15736 with the risk of glioma remained significant in children aged 60 months or older, girls, the subgroups with astrocytic tumors, or grade I+II glioma. We also found the combined effects of five *WDR4* gene polymorphisms on glioma risk. Finally, expression quantitative trait locus (eQTL) analyses elucidated that the rs15736 polymorphism was related to the expression level of *WDR4* and neighboring gene *cystathionine-beta-synthase* (*CBS*). Our finding provided evidence of a causal association between *WDR4* gene polymorphisms and glioma susceptibility in Chinese Han children.

1. Introduction

The annual incidence of primary brain tumors is 6.14 per 100,000 in children under 19 years of age, as declared by the Central Brain Tumor Registry of the United States (CBTRUS). Among them, 11.9% of cases are malignant glioma [1]. Gliomas arise from glial cells of the central nervous system (CNS), including astrocytes, oligodendrocytes, and

ependymal cells. Low-grade gliomas (LGGs), classified as World Health Organization (WHO) grade I or II lesions of the CNS, are generally not lethal [2]. However, due to comorbidities caused by the tumors and/or clinical intervention and their inclination to multiply relapses, the leading brain tumors developed in childhood often demand decades of management [3]. In addition, pediatric high-grade gliomas (pHGGs), classified as grade III or IV lesions, constitute

one-third of gliomas, accountable for the most cancer-related deaths in children younger than 19 years old [4–6].

Environmental factors, including ionizing radiation, some toxic agents (N-nitroso compounds and pesticides), air pollution, and radiofrequency electromagnetic waves, have been suspected to be potentially implicated in the carcinogenesis of brain tumors. However, only ionizing radiation is well-established as a risk factor for brain tumors [7]. On the other hand, heredity is shown to play a role in glioma susceptibility: (1) familial aggregation: individuals with a family history of glioma are at increased risk of developing these tumors. (2) Some well-recognized genetic syndromes confer glioma risk, including the Turcot and Li-Fraumeni syndromes, neurofibromatosis type 1, and multiple enchondromatosis [8]. Moreover, numerous candidate gene association studies provide evidence of a link between genetic variation and glioma predisposition [8–12]. For instance, glioma susceptibility loci have been comprehensively explored in DNA repair, cell cycle, metabolism, and inflammation (including allergies and infections) pathways [8]. Moreover, a dozen glioma susceptibility loci are discovered in *CCDC26*, *PHLDB1*, *TERT*, *RTEL1*, *TP53*, *EGFR*, and *CDKN2A-CDKN2B* genes, using genome-wide association studies (GWASs) [13–16]. Like other cancers, the inherited risk of glioma may be a consequence of the coinheritance of many low-penetrant and low-risk gene single nucleotide polymorphisms (SNPs). It is crucial to identify more risk determinants to understand variations in and refine the predicting capacity of glioma predisposition.

N7-methylguanosine (m⁷G) is one of the most predominant modifications occurring in mRNA, miRNA, and tRNA [17–20]. This type of chemical modification is installed by a specific methyltransferase complex composed of WD repeat domain 4 (WDR4) and methyltransferase-like 1 (METTL1) [21]. WDR4, the non-catalytic component, can stabilize and enhance the methyltransferase activity of METTL1 [21]. m⁷G modification is an essential posttranscriptional mechanism to regulate cell fate and growth. Defective m⁷G tRNA modification caused by *METTL1* knockout impaired the differentiation and growth of embryonic stem cells [22]. Mutation of *WDR4* is causative for a heterogeneous group of microcephalic primordial dwarfism and Galloway-Mowat syndrome [23, 24]. A few publications suggest that dysregulated m⁷G tRNA modification is also implicated in carcinogenesis, including lung cancer, esophageal squamous cell carcinoma, intrahepatic cholangiocarcinoma, head and neck squamous cell carcinoma, and colon cancer [25–30]. Nevertheless, the roles of RNA m⁷G modification have not been reported in glioma. Genome-wide annotation of genetic variation by the Human Genome Project enabled us to evaluate the association between the genetic variants in the *METTL1* and *WDR4* genes and glioma susceptibility in a three-center case-control study (314 cases vs. 380 controls) with Chinese children of Han ethnicity.

2. Methods and Materials

2.1. Study Subjects. Three medical centers participated in this study. Guangzhou Women and Children's Medical Center, Xiangya Hospital, The Second Affiliated Hospital

and Yuying Children's Hospital of Wenzhou Medical University were located in Guangzhou, Changsha, and Wenzhou, respectively [31]. We enrolled 314 cases diagnosed and histopathologically confirmed with glioma regarding the 2016 World Health Organization classification of tumors of the CNS. Blood samples were collected from cases prior to radiotherapy or chemotherapy. A total of 380 cancer-free controls were recruited from the same participating hospitals during the same periods (Table S1). Patients and healthy controls were age and sex-matched. All participants were not genetically related, and their patients or guardians provided written informed consent before the study commencement. The study protocol was authorized by the Institutional Review Boards of the participating hospitals. This study was conducted in accordance with the Declaration of Helsinki.

2.2. SNP Selection and Genotyping. By combining the NCBI dbSNP database and SNPinfo online tool (<https://snpinfonihs.nih.gov/>), we choose three (rs2291617, rs10877013, and rs10877012) and five (rs2156315, rs2156316, rs6586250, rs15736, and rs2248490) potentially functional SNPs in *METTL1* and *WDR4* genes, respectively. Selection criteria were described previously [32, 33]. Genomic DNA was derived from peripheral blood samples of both cases and controls using Tiangen blood DNA extraction kits (Tiangen Biotechnology, Beijing, China). TaqMan genotyping method was adopted to evaluate the genotypes of samples for the selected SNPs with the probes were purchased from ABI (Applied Biosystems, Foster City, CA). All assays were run on an ABI 7900 (Applied Biosystems, Foster City, CA, USA) by the laboratory personnel blind to case/control status of samples. Both negative and positive were routinely included in each 384-well plate. Generally, 10% of samples were genotyped at random, and only a 100% concordance rate of the duplicated samples was accepted.

2.3. Statistical Analysis. The agreement of genotypes with Hardy-Weinberg equilibrium (HWE) was assessed by a goodness-of-fit χ^2 test among control subjects. The demographic features were compared between the cases and controls using the χ^2 test or *t*-test when appropriate. Multivariate logistic regression analyses were used to calculate the odds ratios (ORs) and 95% confidence intervals (CIs) after adjusting for age and sex. We also performed stratified analyses based on age, sex, subtypes, and tumor grade. Expression quantitative trait locus (eQTL) analyses of the significant SNPs were conducted using the Genotype-Tissue Expression (GTEx) (<https://gtexportal.org>). The α of 0.05 was used to define the statistical significance level. All statistical analyses were two-sided and carried out using the SAS v10.0 (SAS Institute, Cary, NC, USA).

3. Results

3.1. Association Study. Single SNP analyses indicated that only the *WDR4* gene rs15736 was significantly associated with glioma susceptibility (GA/AA vs. GG: adjusted OR = 0.63, 95%CI = 0.42 – 0.94, *P* = 0.023) out of the eight

studied SNPs (Table 1). Children harboring minor allele rs15736 A were at a significantly reduced risk of developing glioma compared with those with two G alleles. More, *METTL1* gene rs10877012 was borderline significantly associated with increased glioma risk (adjusted OR = 1.45, 95% CI = 0.95 – 2.21, $P = 0.086$) under the recessive model. It was also the case for *METTL1* gene rs2291617 (adjusted OR = 1.42, 95% CI = 0.94 – 2.16, $P = 0.098$).

3.2. Stratified Analysis. Stratified analyses were performed by age, sex, glioma subtypes, and grades. Stratified analysis for *METTL1* gene SNPs demonstrated no significant association with glioma among any subtypes (Table 2). We also carried out stratified analysis for *WDR4* gene SNPs (Table 3) and found that rs15736 showed significant protective effects in children aged 60 months or older (adjusted OR = 0.58, 95% CI = 0.34 – 0.995, $P = 0.048$), girls (adjusted OR = 0.55, 95% CI = 0.31 – 0.98, $P = 0.042$), the subgroup with astrocytic tumors (adjusted OR = 0.54, 95% CI = 0.34 – 0.87, $P = 0.011$), and those with grade I + II glioma (adjusted OR = 0.58, 95% CI = 0.37 – 0.92, $P = 0.019$). We next conducted a stratified analysis for the combined effect of *WDR4* gene SNPs (Table 3). The concurrence of five indicated protective genotypes exhibited decreased glioma risk in kids presenting astrocytic tumors (adjusted OR = 0.60, 95% CI = 0.35 – 0.90, $P = 0.016$) and those with grade I + II glioma (adjusted OR = 0.60, 95% CI = 0.38 – 0.95, $P = 0.029$).

3.3. Expression Quantitative Trait Locus (eQTL) Analyses. One of the crucial mechanisms underlying the association between causal SNPs and disease risk is affecting the expression levels of host genes. Given the significant association between rs15736 and the risk of glioma, we further assessed the effects of SNP on the expression of the target gene by taking advantage of released data from GTEx. In terms of whole blood, the expression levels of *WDR4* in subjects with AA genotype were significantly enhanced (Figure 1(a)), but the same individuals had the lowest levels of *cystathionine-beta-synthase* (*CBS*) (Figure 1(b)), an adjacent gene of *WDR4* among individuals with GG, GA, and AA genotypes. The data derived from cultured fibroblasts further verified the association of rs15736 AA genotypes with reduced *CBS* levels (Figure 1(c)). The cis-eQTL analysis indicates that rs15736 polymorphism may lead to altered expression of target genes.

4. Discussion

Pediatric glioma seriously threatens the life or impairs the quality of life of affected children. Apart from the environmental risk factors, genetic predisposition for glioma has been substantiated in mounting candidate gene-associated studies and GWASs [9]. Variations in genes involved in DNA repair, cell cycle, metabolism, and inflammation pathways have been recognized as a key basis of inherited glioma susceptibility, such as *PRKDC*, *XRCC1*, *PARP1*, *ERCC1*, *ERCC2*, *EGF*, and *IL13* [34]. Besides, polymorphisms of other important genes also contribute to glioma risk. For instance, a functional SNP rs12803321 with *Solute Carrier*

Family 25 Member 26 as the target gene was found to be a causal locus of LGG [12]. Recently, our group investigated the impacts of SNPs in the RNA m6A modification core genes on pediatric glioma susceptibility. We found that several SNPs were associated with the increased risk of glioma, including the *WTAP* rs7766006, *YTHDF2* rs3738067, and *FTO* rs9939609 polymorphisms [11]. Moreover, compared with adult glioma, genetic association studies are extremely few in pediatric glioma, and the sample sizes of studies are usually small because of the rarity of the disease [34].

In the present moderate-size case-control study, we found that the *WDR4* gene rs15736 was significantly associated with decreased glioma risk. Stratified analysis indicated that the protective effects of rs15736 remained prominent in several subgroups, including children aged 60 months or older, girls, astrocytic tumors, and grade I + II glioma. We also observed decreased glioma susceptibility for children with five protective genotypes in astrocytic tumors and grade I + II glioma subgroups. The findings suggest an association between the *WDR4* gene SNPs and pediatric glioma risk. At present, there are only two studies about genetic variations in the *METTL1/WDR4* gene and diseases. One study demonstrated that the *WDR4* gene rs465663 polymorphism might predispose to asthenozoospermia [35]. The other study, a GWAS performed by the Australian and New Zealand Multiple Sclerosis Genetics Consortium, identified the SNP (rs703842) positioned at the 3' untranslated region (3' UTR) of the *METTL1* gene as a multiple sclerosis susceptibility loci [36].

Over the past years, accumulating evidence is emerging to demonstrate the implication of the *METTL1/WDR4* m⁷G methyltransferase complex in tumorigenesis. The upregulated expression levels of *METTL1* and/or *WDR4* and their association with prognosis were observed in multiple types of cancer, including lung cancer [29], esophageal squamous cell carcinoma (ESCC) [30], intrahepatic cholangiocarcinoma (ICC) [27], hepatocellular carcinoma (HCC) [37], and glioma [38]. Further investigation unveiled that *METTL1/WDR4* accelerated lung cancer cell proliferation and migration by enhancing tRNA m⁷G modification and oncogenic mRNA translation, particularly *CCND3* and *CCNE1*, the cell-cycle regulators [29]. *WDR4* is a partner of *METTL1*, functioning by stabilizing and augmenting the methyltransferase activity of *METTL1*. Therefore, the low level or loss of function of *WDR4* may comprise *METTL1*'s methyltransferase activity to reduce m⁷G tRNA modification. Accumulating evidence has demonstrated the importance of *WDR4* in carcinogenesis and drug resistance. Han et al. observed significantly overexpressed *METTL1* and *WDR4* in ESCC, which were associated with unfavorable outcomes in ESCC. The mechanistic study indicated that silencing *METTL1* or *WDR4* decreased m⁷G-modification levels of tRNAs, thereby downregulating the translation of many oncogenic genes in the RPTOR/ULK1/autophagy pathway [30]. An unbiased proteomic screening of differentially expressed genes between parental and lenvatinib-resistant HCC cells unveiled that *METTL1* and *WDR4* were highly elevated in drug-resistant cells. *METTL1/WDR4*-catalyzed m⁷G tRNA modification led to drug resistance by

TABLE 1: Association of m⁷G modification genes and glioma risk in Chinese children.

Gene	Polymorphism	Allele		Case (N = 312)			Control (N = 380)			P ^a	AOR (95% CI) ^b	P ^b	HWE	
		A	B	AA	AB	BB	AA	AB	BB					
METTL1	rs2291617	G	T	127	129	56	155	175	50	1.00 (0.74-1.36)	0.984	1.42 (0.94-2.16)	0.098	0.956
METTL1	rs10877013	T	C	134	128	50	160	175	45	0.97 (0.71-1.31)	0.837	1.39 (0.90-2.15)	0.142	0.786
METTL1	rs10877012	T	G	129	128	55	152	180	48	0.95 (0.70-1.29)	0.742	1.45 (0.95-2.21)	0.086	0.639
WDR4	rs2156315	C	T	184	113	15	232	135	13	1.10 (0.81-1.50)	0.535	1.47 (0.69-3.14)	0.324	0.213
WDR4	rs2156316	C	G	146	144	22	163	186	31	0.86 (0.64-1.16)	0.323	0.85 (0.48-1.50)	0.563	0.027
WDR4	rs6586250	C	T	261	51	0	301	74	5	0.74 (0.50-1.09)	0.124	/	/	0.852
WDR4	rs15736	G	A	266	46	0	299	76	5	0.63 (0.42-0.94)	0.023	/	/	0.945
WDR4	rs2248490	C	G	148	143	21	165	184	31	0.86 (0.63-1.16)	0.309	0.80 (0.45-1.43)	0.457	0.039

AOR: adjusted odds ratio; CI: confidence interval; HWE: Hardy-Weinberg equilibrium. ^aAdjusted for age and gender for dominant model. ^bAdjusted for age and gender for recessive model.

TABLE 2: Stratification analysis between *METTL1* genotypes and glioma risk.

Variables	rs2291617 (cases/controls)		P ^a	rs10877012 (cases/controls)		P ^a	Risk genotypes ^b (cases/controls)		AOR (95% CI) ^a	P ^a
	GG/GT	TT		TT/TG	GG		0	1-3		
Age, month										
<60	109/153	24/21	0.145	111/155	22/19	0.156	109/153	24/21	1.60 (0.85-3.03)	0.145
≥60	147/177	32/29	0.323	146/177	33/29	0.256	145/177	34/29	1.42 (0.83-2.44)	0.205
Gender										
Females	119/140	26/24	0.513	119/141	26/23	0.420	118/140	27/24	1.29 (0.70-2.36)	0.417
Males	137/190	30/26	0.102	138/191	29/25	0.113	136/190	31/26	1.67 (0.95-2.94)	0.076
Subtypes										
Astrocytic tumors	173/330	39/50	0.101	173/332	39/48	0.076	171/330	41/50	1.56 (0.99-2.47)	0.057
Ependymoma	51/330	10/50	0.366	52/332	9/48	0.461	51/330	10/50	1.42 (0.66-3.03)	0.366
Neuronal and mixed	20/330	5/50	0.325	20/332	5/48	0.287	20/330	5/50	1.68 (0.60-4.70)	0.325
Embryonal tumors	10/330	2/50	0.934	10/332	2/48	0.954	10/330	2/50	0.93 (0.19-4.71)	0.934
Clinical stages										
I + II	183/330	41/50	0.103	186/332	38/48	0.169	183/330	41/50	1.46 (0.93-2.29)	0.103
III + IV	72/330	15/50	0.388	70/332	17/48	0.131	70/330	17/50	1.54 (0.83-2.84)	0.168

AOR: adjusted odds ratio; CI: confidence interval. ^aAdjusted for age and gender, omitting the corresponding stratify factor. ^bRisk genotypes were carriers with rs2291617 TT, rs10877013 CC, and rs10877012 GG genotypes.

TABLE 3: Stratification analysis between WDR4 genotypes and glioma risk.

Variables	rs15736 (cases/controls)		AOR (95% CI) ^a	P ^a	Protective genotypes ^b (cases/controls)		AOR (95% CI) ^a	P ^a
	GG	GA/AA			0-4	5		
Age, month								
<60	112/138	21/36	0.71 (0.39-1.29)	0.256	112/139	21/35	0.73 (0.40-1.34)	0.312
≥60	154/161	25/45	0.58 (0.34-0.995)	0.048	154/162	25/44	0.60 (0.35-1.02)	0.061
Gender								
Females	123/123	22/41	0.55 (0.31-0.98)	0.042	123/124	22/40	0.57 (0.32-1.01)	0.055
Males	143/176	24/40	0.72 (0.41-1.25)	0.238	143/177	24/39	0.74 (0.42-1.29)	0.291
Subtypes								
Astrocytic tumors	184/299	28/81	0.54 (0.34-0.87)	0.011	184/301	28/79	0.60 (0.35-0.90)	0.016
Ependymoma	50/299	11/81	0.82 (0.40-1.67)	0.575	50/301	11/79	0.84 (0.41-1.71)	0.620
Neuronal and mixed	21/299	4/81	0.73 (0.24-2.19)	0.572	21/301	4/79	0.75 (0.25-2.27)	0.614
Embryonal tumors	10/299	2/81	0.72 (0.15-3.40)	0.673	10/301	2/79	0.74 (0.16-3.53)	0.706
Clinical stages								
I + II	193/299	31/81	0.58 (0.37-0.92)	0.019	193/301	31/79	0.60 (0.38-0.95)	0.029
III + IV	73/299	14/81	0.70 (0.37-1.30)	0.257	73/301	14/79	0.72 (0.39-1.35)	0.307

AOR: adjusted odds ratio; CI: confidence interval. ^aAdjusted for age and gender, omitting the corresponding stratify factor. ^bProtective genotypes were carriers with rs2156315 CC/CT, rs2156316 CG/GG, rs6586250 CT/TT, rs15736 GA/AA, and rs2248490 CG/GG genotypes.




FIGURE 1: Expression quantitative trait loci (eQTL) analyses of *MDR4* gene rs15736 polymorphism using the public database GTEx portal. (a) The genotype of rs15736 and expression of *MDR4* gene in whole blood. (b) The genotype of rs15736 and expression of its nearby gene *CBS* in whole blood. (c) The genotype of rs15736 and expression of the *CBS* gene in cultured fibroblasts.

facilitating the translation of EGFR pathway genes. *METTL1* depletion overcame resistance by inhibiting proliferation and inducing apoptosis of HCC cells [39]. In ICC, *METTL1* and *WDR4* enhanced the translation of cell-cycle and epidermal growth factor receptor (EGFR) pathway genes in an m^7G -tRNA-dependent manner. On the contrary, some groups found that MTC may also be tumor-suppressing [19, 28]. Pandolfini et al.'s study indicated that the *METTL1* increased tumor suppressor let-7 miRNA levels and thereby suppressed lung cancer cell migration [19]. Mechanistic investigation elucidated that besides translation regulation, *METTL1* can also catalyze m^7G modification of the primary miRNA transcript (pri-miRNA) to affect their processing. The m^7G in precursors of let-7 miRNA interrupted inhibitory RNA secondary structures so as to expedite its maturation [19]. Another group reported that *METTL1* inhibited colon cancer by increasing let-7e miRNA and decreasing its target gene *HMG2A2*. Moreover, overexpression of *METTL1* enhanced the cytotoxic effects of cisplatin on colon cancer cells by triggering the miR-149-3p/S100A4/p53 axis [28]. Thus far, only one publication showed the potential implication of m^7G methyltransferase complex *METTL1*/*WDR4* in glioma. Expression of *METTL1* was augmented in glioma in comparison to normal tissue, and its expression

levels were inversely associated with prognosis in glioma. In vitro experiments revealed that silencing of *METTL1* led to retardation of glioma cell growth [38]. However, several studies demonstrated the crucial role of m^7G in neurodevelopment. MTC is in charge of installing the highly conserved m^7G_{46} (7-methylguanosine) modification in tRNA. tRNA is well-known to facilitate protein synthesis by transporting amino acids to the expanding peptide chain during the corresponding mRNA translation. Intriguingly, the brain seems to be vulnerable to dysregulated tRNA modification. Recently, Shaheen et al. reported that mutation in *WDR4* disrupted tRNA m^7G_{46} methylation, consequently leading to microcephalic primordial dwarfism [23]. Consistently, Braun et al. discovered a disease-causing mutation in the *WDR4* gene for Galloway-Mowat syndrome (GAMOS) characterized by neurodevelopmental defects [24]. Coincidentally, Lin et al.'s group demonstrated that the knockout of *METTL1* in mouse embryonic stem cells (mESCs) preferentially affected the translation of cell cycle genes and genes associated with brain abnormalities. Moreover, self-renewal and neural differentiation of *METTL1* or *WDR4* knockout mESCs were severely impeded [40]. Overall, *METTL1* may play context-dependent roles in tumorigenesis. In the current study, our results support *METTL1* as a pediatric

glioma susceptibility gene. The underpinning mechanism of how *METTL1* SNPs modify glioma susceptibility warrants further investigation.

Interestingly, we also found that *WDR4* SNP rs15736 was associated with an alteration in the expression of a neighboring gene *CBS*. *CBS* is an enzyme that generally forms a homotetramer to convert homocysteine to cystathionine, the first reaction in the transsulfuration pathway. *CBS* is dysregulated in different types of cancer, which is upregulated in kidney, colorectal, ovarian, lung, and breast cancer but downregulated in glioma and liver cancer. The low expression level of *CBS* is associated with poor survival in cancers with *CBS* as a tumor suppressor [41]. Zheng et al. reported that Apolipoprotein C1 could facilitate glioblastoma tumorigenesis by inhibiting *CBS*-mediated ferroptosis, suggesting that reduced expression may help to maintain glioblastoma cell survival by reducing ferroptosis [42]. These results suggest that affecting nearby genes is an alternative mechanism by which an SNP modifies disease susceptibility.

Several limitations of the study should be addressed. First, pediatric glioma is a rare disease. Although we recruited samples from three independent medical centers, the sample size of our cohort is still moderate. Second, gene-gene and gene-environment interactions were not taken into account. Third, functional experiments need to be performed to evaluate the effect of significant SNPs on gene expression. Finally, the effects of the SNP on the survival of glioma patients should be estimated. Unfortunately, we have no survival information on these glioma patients. Besides, no public database is available to evaluate the effect of polymorphisms on pediatric glioma patient survival by Kaplan-Meier analysis.

5. Conclusion

In conclusion, we identified glioma susceptibility loci in the *WDR4* gene for Chinese Han Children. Validation studies should be conducted in different populations.

Abbreviations

CNS:	Central nervous system
m ⁷ G:	N7-methylguanosine
eQTL:	Expression quantitative trait loci
CBTRUS:	Central Brain Tumor Registry of the United States
LGG:	Low-grade glioma
WHO:	World Health Organization
pHGG:	Pediatric high-grade glioma
GWAS:	Genome-wide association study
SNP:	Single nucleotide polymorphism
WDR4:	WD repeat domain 4
METTL1:	Methyltransferase-like 1
HWE:	Hardy-Weinberg equilibrium
OR:	Odds ratio
CI:	Confidence interval
GTE _x :	Genotype-tissue expression
UTR:	Untranslated region
ESCC:	Esophageal squamous cell carcinoma

ICC:	Intrahepatic cholangiocarcinoma
HCC:	Hepatocellular carcinoma
EGFR:	Epidermal growth factor receptor
pri-miRNA:	Primary miRNA
mESC:	Mouse embryonic stem cell.

Data Availability

All the data were available upon request.

Conflicts of Interest

The authors declare no competing financial interests.

Authors' Contributions

All authors contributed significantly to this work. JH and JR designed the experiments, supervised the project, and were involved in all aspects of the submission. JZ, XL, WC, YL, JL, LY, JR, and JH performed the experiments and participated in the study design, data analysis, and manuscript preparation. All authors read and approved the final manuscript. Jinhong Zhu, Xiaoping Liu, and Wei Chen contributed equally to this work.

Acknowledgments

This study was supported by grants from the National Natural Science Foundation of China (no. 81802346) and Guangdong Provincial Key Laboratory of Research in Structural Birth Defect Disease (no. 2019B030301004).

Supplementary Materials

Table S1: frequency distribution of selected variables in glioma patients and cancer-free controls in combined subjects. (*Supplementary Materials*)

References

- [1] Q. T. Ostrom, N. Patil, G. Cioffi, K. Waite, C. Kruchko, and J. S. Barnholtz-Sloan, "CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017," *Neuro-Oncology*, vol. 22, Supplement_1, p. iv1, 2020.
- [2] D. T. W. Jones, M. W. Kieran, E. Bouffet et al., "Pediatric low-grade gliomas: next biologically driven steps," *Neuro-Oncology*, vol. 20, no. 2, pp. 160–173, 2018.
- [3] T. A. Bale and M. K. Rosenblum, "The 2021 WHO classification of tumors of the central nervous system: an update on pediatric low-grade gliomas and glioneuronal tumors," *Brain Pathology*, vol. 32, no. 4, article e13060, 2022.
- [4] J. L. Ross, J. Velazquez Vega, A. Plant, T. J. MacDonald, O. J. Becher, and D. Hambardzumyan, "Tumour immune landscape of paediatric high-grade gliomas," *Brain*, vol. 144, no. 9, pp. 2594–2609, 2021.
- [5] J. Pearce, K. Khabra, H. Nanji et al., "High grade gliomas in young children: the South Thames Neuro-Oncology unit experience and recent advances in molecular biology and targeted therapies," *Pediatric Hematology and Oncology*, vol. 38, no. 8, pp. 707–721, 2021.

- [6] L. Pinto, H. Baidarjad, N. Entz-Werlé, and E. Van Dyck, "Impact of chromatin dynamics and DNA repair on genomic stability and treatment resistance in pediatric high-grade gliomas," *Cancers (Basel)*, vol. 13, no. 22, p. 5678, 2021.
- [7] A. Vienne-Jumeau, C. Tafani, and D. Ricard, "Environmental risk factors of primary brain tumors: a review," *Revue Neurologique (Paris)*, vol. 175, no. 10, pp. 664–678, 2019.
- [8] J. Gu, Y. Liu, A. P. Kyritsis, and M. L. Bondy, "Molecular epidemiology of primary brain tumors," *Neurotherapeutics*, vol. 6, no. 3, pp. 427–435, 2009.
- [9] C. B. Tavares, F. das Chagas Sheyla Almeida Gomes-Braga, E. B. Sousa et al., "Association between single nucleotide polymorphisms and glioma risk: a systematic literature review," *Cancer Investigation*, vol. 38, no. 3, pp. 169–183, 2020.
- [10] M. W. Ali, C. P. K. Patro, J. J. Zhu et al., "A functional variant on 20q13.33 related to glioma risk alters enhancer activity and modulates expression of multiple genes," *Human Mutation*, vol. 42, no. 1, pp. 77–88, 2021.
- [11] J. He, L. Yuan, H. Lin et al., "Genetic variants in m⁶A modification core genes are associated with glioma risk in Chinese children," *Molecular Therapy - Oncolytics*, vol. 20, pp. 199–208, 2021.
- [12] M. Manjunath, J. Yan, Y. Youn et al., "Functional analysis of low-grade glioma genetic variants predicts key target genes and transcription factors," *Neuro-Oncology*, vol. 23, no. 4, pp. 638–649, 2021.
- [13] B. Kinnersley, M. Labussiere, A. Holroyd et al., "Genome-wide association study identifies multiple susceptibility loci for glioma," *Nature Communications*, vol. 6, no. 1, p. 8559, 2015.
- [14] B. S. Melin, J. S. Barnholtz-Sloan, M. R. Wrensch et al., "Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors," *Nature Genetics*, vol. 49, no. 5, pp. 789–794, 2017.
- [15] M. Wrensch, R. B. Jenkins, J. S. Chang et al., "Variants in the *CDKN2B* and *RTEL1* regions are associated with high-grade glioma susceptibility," *Nature Genetics*, vol. 41, no. 8, pp. 905–908, 2009.
- [16] S. Shete, F. J. Hosking, L. B. Robertson et al., "Genome-wide association study identifies five susceptibility loci for glioma," *Nature Genetics*, vol. 41, no. 8, pp. 899–904, 2009.
- [17] S. Zaccara, R. J. Ries, and S. R. Jaffrey, "Reading, writing and erasing mRNA methylation," *Nature Reviews Molecular Cell Biology*, vol. 20, no. 10, pp. 608–624, 2019.
- [18] E. A. Orellana, Q. Liu, E. Yankova et al., "METTL1-mediated m⁷G modification of Arg-TCT tRNA drives oncogenic transformation," *Molecular Cell*, vol. 81, no. 16, pp. 3323–3338.e14, 2021.
- [19] L. Pandolfini, I. Barbieri, A. J. Bannister et al., "METTL1 Promotes *let-7* MicroRNA Processing via m⁷G Methylation," *Molecular Cell*, vol. 74, no. 6, pp. 1278–1290.e9, 2019.
- [20] L. S. Zhang, C. Liu, H. Ma et al., "Transcriptome-wide Mapping of Internal N⁷-Methylguanosine Methylome in Mammalian mRNA," *Molecular Cell*, vol. 74, no. 6, pp. 1304–1316.e8, 2019.
- [21] A. Alexandrov, M. R. Martzen, and E. M. Phizicky, "Two proteins that form a complex are required for 7-methylguanosine modification of yeast tRNA," *RNA*, vol. 8, no. 10, pp. 1253–1266, 2002.
- [22] Y. Liu, Y. Zhang, Q. Chi, Z. Wang, and B. Sun, "Retracted: Methyltransferase-like 1 (METTL1) served as a tumor suppressor in colon cancer by activating 7-methylguanosine (m⁷G) regulated *let-7e* miRNA/HMGA2 axis," *Life Sciences*, vol. 249, article 117480, 2020.
- [23] R. Shaheen, G. M. Abdel-Salam, M. P. Guy et al., "Mutation in *WDR4* impairs tRNA m⁷G₄₆ methylation and causes a distinct form of microcephalic primordial dwarfism," *Genome Biology*, vol. 16, no. 1, p. 210, 2015.
- [24] D. A. Braun, S. Shril, A. Sinha et al., "Mutations in *WDR4* as a new cause of Galloway-Mowat syndrome," *American Journal of Medical Genetics Part A*, vol. 176, no. 11, pp. 2460–2465, 2018.
- [25] J. Chen, K. Li, J. Chen et al., "Aberrant translation regulated by METTL1/*WDR4*-mediated tRNA N⁷-methylguanosine modification drives head and neck squamous cell carcinoma progression," *Cancer Communications*, vol. 42, no. 3, pp. 223–244, 2022.
- [26] Z. Chen, W. Zhu, S. Zhu et al., "METTL1 promotes hepatocarcinogenesis via m⁷G tRNA modification-dependent translation control," *Clinical and Translational Medicine*, vol. 11, no. 12, article e661, 2021.
- [27] Z. Dai, H. Liu, J. Liao et al., "N⁷-Methylguanosine tRNA modification enhances oncogenic mRNA translation and promotes intrahepatic cholangiocarcinoma progression," *Molecular Cell*, vol. 81, no. 16, pp. 3339–3355.e8, 2021.
- [28] Y. Liu, C. Yang, Y. Zhao, Q. Chi, Z. Wang, and B. Sun, "Overexpressed methyltransferase-like 1 (METTL1) increased chemosensitivity of colon cancer cells to cisplatin by regulating miR-149-3p/S100A4/p53 axis," *Ageing (Albany NY)*, vol. 11, no. 24, pp. 12328–12344, 2019.
- [29] J. Ma, H. Han, Y. Huang et al., "METTL1/*WDR4*-mediated m⁷G tRNA modifications and m⁷G codon usage promote mRNA translation and lung cancer progression," *Molecular Therapy*, vol. 29, no. 12, pp. 3422–3435, 2021.
- [30] H. Han, C. Yang, J. Ma et al., "N⁷-methylguanosine tRNA modification promotes esophageal squamous cell carcinoma tumorigenesis via the RPTOR/ULK1/autophagy axis," *Nature Communications*, vol. 13, no. 1, p. 1478, 2022.
- [31] Y. P. Chen, Y. X. Liao, Z. J. Zhuo et al., "Association between genetic polymorphisms of base excision repair pathway and glioma susceptibility in Chinese children," *World Journal of Pediatrics*, vol. 18, no. 9, pp. 632–635, 2022.
- [32] Z. Zhuo, H. Lu, J. Zhu et al., "METTL14 gene polymorphisms confer neuroblastoma susceptibility: an eight-center case-control study," *Molecular Therapy - Nucleic Acids*, vol. 22, pp. 17–26, 2020.
- [33] J. Bian, Z. Zhuo, J. Zhu et al., "Association between METTL3 gene polymorphisms and neuroblastoma susceptibility: a nine-centre case-control study," *Journal of Cellular and Molecular Medicine*, vol. 24, no. 16, pp. 9280–9286, 2020.
- [34] Y. Liu, S. Shete, F. Hosking, L. Robertson, R. Houlston, and M. Bondy, "Genetic advances in glioma: susceptibility genes and networks," *Current Opinion in Genetics & Development*, vol. 20, no. 3, pp. 239–244, 2010.
- [35] Y. J. Wang, E. Mugiyanto, Y. T. Peng et al., "Genetic association of the functional *WDR4* gene in male fertility," *Journal of Personalized Medicine*, vol. 11, no. 8, p. 760, 2021.
- [36] The Australia and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene), "Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20," *Nature Genetics*, vol. 41, no. 7, pp. 824–828, 2009.
- [37] Q. H. Tian, M. F. Zhang, J. S. Zeng et al., "METTL1 overexpression is correlated with poor prognosis and promotes

- hepatocellular carcinoma via PTEN,” *Journal of Molecular Medicine (Berlin, Germany)*, vol. 97, no. 11, pp. 1535–1545, 2019.
- [38] L. Li, Y. Yang, Z. Wang, C. Xu, J. Huang, and G. Li, “Prognostic role of METTL1 in glioma,” *Cancer Cell International*, vol. 21, no. 1, p. 633, 2021.
- [39] M. Huang, J. Long, Z. Yao et al., “METTL1-mediated m⁷G tRNA modification promotes lenvatinib resistance in hepatocellular carcinoma,” *Cancer Research*, vol. 83, no. 1, pp. 89–102, 2023.
- [40] S. Lin, Q. Liu, V. S. Lelyveld, J. Choe, J. W. Szostak, and R. I. Gregory, “Mettl1/Wdr4-Mediated m⁷G tRNA Methylome Is Required for Normal mRNA Translation and Embryonic Stem Cell Self-Renewal and Differentiation,” *Molecular Cell*, vol. 71, no. 2, pp. 244–255.e5, 2018.
- [41] K. Ascencao and C. Szabo, “Emerging roles of cystathionine β -synthase in various forms of cancer,” *Redox Biology*, vol. 53, article 102331, 2022.
- [42] X. J. Zheng, W. L. Chen, J. Yi et al., “Apolipoprotein C1 promotes glioblastoma tumorigenesis by reducing KEAP1/NRF2 and CBS-regulated ferroptosis,” *Acta Pharmacologica Sinica*, vol. 43, no. 11, pp. 2977–2992, 2022.